Related Experiment Video
Updated: Feb 20, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
Expression of miR-126 and its potential function in coronary artery disease
Xiaoyan Wang1, Yajun Lian2, Xin Wen3
1Department of Ultrasound, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
Insights
MicroRNA-126 (miR-126) is down-regulated in coronary artery disease (CAD) patients. Lower miR-126 levels may indicate CAD, suggesting its potential as a novel biomarker for the condition.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biomarker Discovery
Background:
- Coronary artery disease (CAD) poses a significant global health burden.
- Identifying reliable biomarkers for early detection and management of CAD is crucial.
- MicroRNAs (miRNAs) are emerging as key regulators in cardiovascular pathophysiology.
Purpose of the Study:
- To investigate the expression levels of miR-126 in patients with coronary artery disease (CAD).
- To explore the potential role of miR-126 and its targets in the development of atherosclerosis.
- To assess the association between miR-126 and clinical indicators in CAD.
Main Methods:
- Real-time quantitative PCR was employed to measure plasma miR-126 levels in 60 CAD patients and 25 healthy controls.
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify plasma levels of placenta growth factor (PLGF).
- CAD patients were stratified into stable angina pectoris (SAP), unstable angina pectoris (UAP), and acute myocardial infarction (AMI) groups.
Main Results:
- Plasma miR-126 expression was significantly lower in CAD patients compared to healthy controls (P<0.01).
- Plasma PLGF levels were significantly elevated in patients with UAP and AMI compared to controls (P<0.01).
- A significant inverse association was observed between miR-126 expression and PLGF levels in patients with AMI.
Conclusions:
- miR-126 may serve as a novel and valuable biomarker for the diagnosis of coronary artery disease.
- The down-regulation of miR-126 in CAD suggests its involvement in the atherosclerotic process.
- Further research is warranted to elucidate the precise mechanisms underlying miR-126's role in CAD.
Objective:
This study aimed to explore the role of miR-126 in coronary artery disease (CAD) patients and the potential gene targets of miR-126 in atherosclerosis.
Methodology:
A total of 60 CAD patients and 25 healthy control subjects were recruited in this study. Among the 60 CAD patients, 18 cases were diagnosed of stable angina pectoris (SAP), 20 were diagnosed of unstable angina pectoris (UAP) and 22 were diagnosed of acute myocardial infarction (AMI). Plasma miR-126 levels from both groups of participants were analyzed by real-time quantitative PCR. ELISA was used to measure plasma level of placenta growth factor (PLGF).
Results:
The results showed that the miR-126 expression was significantly down-regulated in the circulation of CAD patients compared with control subjects (P<0.01). Plasma PLGF level was significantly upregulated in patients with unstable angina pectoris and acute myocardial infarction (AMI) compared with controls (both P<0.01) the miR-126 expression in AMI was significantly associated with PLGF.
Conclusion:
miR-126 may serve as a novel biomarker for CAD.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
MicroRNAs
MicroRNAs
Coronary Artery Disease III: Clinical Manifestations
Myocarditis I: Introduction

